You have 9 free searches left this month | for more free features.

CART cells

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Castrate-Resistant Prostate Cancer Trial in Shanghai (LIGHT-PSMA-CART cells)

Suspended
  • Castrate-Resistant Prostate Cancer
  • LIGHT-PSMA-CART cells
  • Shanghai, Shanghai, China
    Changhai Hospital
Jan 25, 2023

Solid Tumor Trial (HER2-E-CART cells)

Not yet recruiting
  • Solid Tumor
  • HER2-E-CART cells
  • (no location specified)
Feb 16, 2023

Malignant Tumors of Digestive Organs Trial in Hangzhou (gucy2c cart cells)

Recruiting
  • Malignant Neoplasms of Digestive Organs
  • gucy2c cart cells
  • Hangzhou, Zhejiang, China
    First affiliated hospital, Zhejiang University
Feb 26, 2022

Prostate Cancer Trial in Beijing (CART-PSMA cells)

Recruiting
  • Prostate Cancer
  • CART-PSMA cells
  • Beijing, China
    Chinese PLA General Hospital
Dec 12, 2022

Multiple Myeloma Trial in Philadelphia (CART-19 cells)

Terminated
  • Multiple Myeloma
  • CART-19 cells
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 4, 2023

Acute Myeloid Leukemia Trial in Kunming (Anti-CLL1 CART cells)

Recruiting
  • Acute Myeloid Leukemia
  • Anti-CLL1 CART cells
  • Kunming, Yunnan, China
    No.212 Daguan Road, Xishan District
Nov 23, 2022

Castrate-Resistant Prostate Cancer Trial in Hangzhou (PD1-PSMA-CART cells)

Recruiting
  • Castrate-Resistant Prostate Cancer
  • PD1-PSMA-CART cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University
Feb 26, 2022

Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) Trial (3x10(6) CART-38 cellls, 7x10(5) CART-38 cells, 7x10(6) CART-38 cells)

Not yet recruiting
  • Acute Myeloid Leukemia (AML)
  • Multiple Myeloma (MM)
  • 3x10(6) CART-38 cellls
  • +5 more
  • (no location specified)
Jul 15, 2022

Leukemia, Myeloid, Acute Trial (CD33KO-HSPC; CART33)

Not yet recruiting
  • Leukemia, Myeloid, Acute
  • CD33KO-HSPC; CART33
  • (no location specified)
Jul 13, 2023

Prostate Cancer Trial in Philadelphia (CART-PSMA-TGFßRDN cells, Cyclophosphamide, Fludarabine)

Recruiting
  • Prostate Cancer
  • CART-PSMA-TGFβRDN cells
  • +2 more
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Mar 17, 2022

B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B Lineage Lymphoblastic Lymphoma
  • Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
  • Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 25, 2023

Study for Patients Treat With WU-CART-007

Enrolling by invitation
  • T-cell Acute Lymphoblastic Leukemia
  • T-cell Lymphoblastic Lymphoma
  • Genetic: WU-CART-007
  • Saint Louis, Missouri
    Washington University
Aug 18, 2022

Quality Of Life and Drug Use in Patients With CAR-T Cells

Recruiting
  • Patients With Diffuse Large B-cell Lymphoma Treated With CART-cells
  • Semi-structured interviews and self-administered questionnaires
  • Pierre-Bénite, France
    Hospices Civils de Lyon -Groupement Hospitalier Sud Service phar
Feb 1, 2022

Metastatic Medullary Thyroid Cancer Trial in Philadelphia (single dose of CART-GFRa4 cells, Fludarabine, Cyclophosphamide)

Recruiting
  • Metastatic Medullary Thyroid Cancer
  • single dose of CART-GFRa4 cells
  • +2 more
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Sep 16, 2022

Neuroblastoma, Effects of Immunotherapy Trial in Guangzhou (Anti-GD2 CART)

Suspended
  • Neuroblastoma
  • Effects of Immunotherapy
  • Anti-GD2 CART
  • Guangzhou, Guangdong, China
    Zhujiang Hospital of Southern Medical University
Aug 2, 2021

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022

Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma Trial in Houston (C7R-GD2.CART cells, Cyclophosphamide,

Recruiting
  • Relapsed Neuroblastoma
  • +6 more
  • C7R-GD2.CART cells
  • +2 more
  • Houston, Texas
  • +1 more
Nov 12, 2021

T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

Not yet recruiting
  • T-Cell Non-Hodgkin Lymphoma
  • +14 more
  • WU-CART-007
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 17, 2023

B-cell Non Hodgkin Lymphoma Trial in Augsburg, Cologne, Hamburg (MB-CART2019.1 Dose level 1, MB-CART2019.1 Dose level 2)

Active, not recruiting
  • B-cell Non Hodgkin Lymphoma
  • MB-CART2019.1 Dose level 1
  • MB-CART2019.1 Dose level 2
  • Augsburg, Bavaria, Germany
  • +2 more
Jun 13, 2022

Brain and Nervous System Trial in Palo Alto (B7-H3CART)

Recruiting
  • Brain and Nervous System
  • Palo Alto, California
    Stanford Cancer Institute
Jul 22, 2022

Pancreatic Cancer Trial in Shatin (MSLN CART)

Not yet recruiting
  • Pancreatic Cancer
  • MSLN CART
  • Shatin, N.t., Hong Kong
    Endoscopy Centre, Prince of Wales Hospital
Sep 19, 2023

Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase

Recruiting
  • Lymphoblastic Leukemia
  • +4 more
  • Phase I
  • Phase II
  • Singapore, Singapore
    KK Women's and Children's hospital
Jun 20, 2022

T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

Not yet recruiting
  • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
  • CD7-CART01
  • (no location specified)
Sep 26, 2023

Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Suzhou (CD19/22 CART, Tislelizumab)

Unknown status
  • Relapsed Non Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 30, 2021

B-cell Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma Trial in Aurora (CD19CAR-CD3Zeta-4-1BB-Expressing Autologous

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-cell Non Hodgkin Lymphoma
  • CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
  • Aurora, Colorado
    Children's Hospital Colorado
Nov 9, 2022